Amgen Inc. Stock News

The Investment Committee give you their top stocks to watch for the second half.

In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.

Amgen has been busy with a couple of multi-billion dollar acquisitions over the past few years. While they should create growth opportunities, the drugmaker has also taken on quite a bit of debt.

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

Looking ahead, the future of the U.S. economy appears promising despite ongoing challenges. President Biden's efforts to steer the economy through inflation concerns are showing strong results.

Amgen's lineup and pipeline should help its financial results and keep its dividend intact. While lesser known, Sarepta is proving itself to be a highly innovative biotech company.

Amgen (AMGN) concluded the recent trading session at $269.95, signifying a +0.69% move from its prior day's close.

As the retirement crisis looms, urgent action is key. The financial industry's failure to address rising retirement costs exacerbates the situation. Investing in dividend-growth stocks emerges as a cr

Amgen AMGN is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health, nephrology and neur

The popular iShares Biotechnology ETF NASDAQ: IBB has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.

Amgen (AMGN) closed the most recent trading day at $283.04, moving -0.45% from the previous trading session.

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity candi

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.